Global Tumor Necrosis Factor Inhibitor Drug Market Growth 2022-2028

1.1 Market Introduction

1.2 Years Considered

1.3 Research Objectives

1.4 Market Research Methodology

1.5 Research Process and Data Source

1.6 Economic Indicators

1.7 Currency Considered

2 Executive Summary

2.1 World Market Overview

2.1.1 Global Tumor Necrosis Factor Inhibitor Drug Annual Sales 2017-2028

2.1.2 World Current & Future Analysis for Tumor Necrosis Factor Inhibitor Drug by Geographic Region, 2017, 2022 & 2028

2.1.3 World Current & Future Analysis for Tumor Necrosis Factor Inhibitor Drug by Country/Region, 2017, 2022 & 2028

2.2 Tumor Necrosis Factor Inhibitor Drug Segment by Type

2.2.1 Humira

2.2.2 Enbrel

2.2.3 Remicade

2.2.4 Simponi

2.2.5 Cimzia

2.2.6 Biosimilars

2.3 Tumor Necrosis Factor Inhibitor Drug Sales by Type

2.3.1 Global Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Type (2017-2022)

2.3.2 Global Tumor Necrosis Factor Inhibitor Drug Revenue and Market Share by Type (2017-2022)

2.3.3 Global Tumor Necrosis Factor Inhibitor Drug Sale Price by Type (2017-2022)

2.4 Tumor Necrosis Factor Inhibitor Drug Segment by Application

2.4.1 Rheumatoid Arthritis

2.4.2 Psoriatic Arthritis

2.4.3 Juvenile Idiopathic Arthritis

2.4.4 Crohn’s Disease

2.4.5 Ulcerative Colitis

2.4.6 Others

2.5 Tumor Necrosis Factor Inhibitor Drug Sales by Application

2.5.1 Global Tumor Necrosis Factor Inhibitor Drug Sale Market Share by Application (2017-2022)

2.5.2 Global Tumor Necrosis Factor Inhibitor Drug Revenue and Market Share by Application (2017-2022)

2.5.3 Global Tumor Necrosis Factor Inhibitor Drug Sale Price by Application (2017-2022)

3 Global Tumor Necrosis Factor Inhibitor Drug by Company

3.1 Global Tumor Necrosis Factor Inhibitor Drug Breakdown Data by Company

3.1.1 Global Tumor Necrosis Factor Inhibitor Drug Annual Sales by Company (2020-2022)

3.1.2 Global Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Company (2020-2022)

3.2 Global Tumor Necrosis Factor Inhibitor Drug Annual Revenue by Company (2020-2022)

3.2.1 Global Tumor Necrosis Factor Inhibitor Drug Revenue by Company (2020-2022)

3.2.2 Global Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Company (2020-2022)

3.3 Global Tumor Necrosis Factor Inhibitor Drug Sale Price by Company

3.4 Key Manufacturers Tumor Necrosis Factor Inhibitor Drug Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Tumor Necrosis Factor Inhibitor Drug Product Location Distribution

3.4.2 Players Tumor Necrosis Factor Inhibitor Drug Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)

3.6 New Products and Potential Entrants

3.7 Mergers & Acquisitions, Expansion

4 World Historic Review for Tumor Necrosis Factor Inhibitor Drug by Geographic Region

4.1 World Historic Tumor Necrosis Factor Inhibitor Drug Market Size by Geographic Region (2017-2022)

4.1.1 Global Tumor Necrosis Factor Inhibitor Drug Annual Sales by Geographic Region (2017-2022)

4.1.2 Global Tumor Necrosis Factor Inhibitor Drug Annual Revenue by Geographic Region

4.2 World Historic Tumor Necrosis Factor Inhibitor Drug Market Size by Country/Region (2017-2022)

4.2.1 Global Tumor Necrosis Factor Inhibitor Drug Annual Sales by Country/Region (2017-2022)

4.2.2 Global Tumor Necrosis Factor Inhibitor Drug Annual Revenue by Country/Region

4.3 Americas Tumor Necrosis Factor Inhibitor Drug Sales Growth

4.4 APAC Tumor Necrosis Factor Inhibitor Drug Sales Growth

4.5 Europe Tumor Necrosis Factor Inhibitor Drug Sales Growth

4.6 Middle East & Africa Tumor Necrosis Factor Inhibitor Drug Sales Growth

5 Americas

5.1 Americas Tumor Necrosis Factor Inhibitor Drug Sales by Country

5.1.1 Americas Tumor Necrosis Factor Inhibitor Drug Sales by Country (2017-2022)

5.1.2 Americas Tumor Necrosis Factor Inhibitor Drug Revenue by Country (2017-2022)

5.2 Americas Tumor Necrosis Factor Inhibitor Drug Sales by Type

5.3 Americas Tumor Necrosis Factor Inhibitor Drug Sales by Application

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Tumor Necrosis Factor Inhibitor Drug Sales by Region

6.1.1 APAC Tumor Necrosis Factor Inhibitor Drug Sales by Region (2017-2022)

6.1.2 APAC Tumor Necrosis Factor Inhibitor Drug Revenue by Region (2017-2022)

6.2 APAC Tumor Necrosis Factor Inhibitor Drug Sales by Type

6.3 APAC Tumor Necrosis Factor Inhibitor Drug Sales by Application

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 Europe

7.1 Europe Tumor Necrosis Factor Inhibitor Drug by Country

7.1.1 Europe Tumor Necrosis Factor Inhibitor Drug Sales by Country (2017-2022)

7.1.2 Europe Tumor Necrosis Factor Inhibitor Drug Revenue by Country (2017-2022)

7.2 Europe Tumor Necrosis Factor Inhibitor Drug Sales by Type

7.3 Europe Tumor Necrosis Factor Inhibitor Drug Sales by Application

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 Middle East & Africa

8.1 Middle East & Africa Tumor Necrosis Factor Inhibitor Drug by Country

8.1.1 Middle East & Africa Tumor Necrosis Factor Inhibitor Drug Sales by Country (2017-2022)

8.1.2 Middle East & Africa Tumor Necrosis Factor Inhibitor Drug Revenue by Country (2017-2022)

8.2 Middle East & Africa Tumor Necrosis Factor Inhibitor Drug Sales by Type

8.3 Middle East & Africa Tumor Necrosis Factor Inhibitor Drug Sales by Application

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 Market Drivers, Challenges and Trends

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 Manufacturing Cost Structure Analysis

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Tumor Necrosis Factor Inhibitor Drug

10.3 Manufacturing Process Analysis of Tumor Necrosis Factor Inhibitor Drug

10.4 Industry Chain Structure of Tumor Necrosis Factor Inhibitor Drug

11 Marketing, Distributors and Customer

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Tumor Necrosis Factor Inhibitor Drug Distributors

11.3 Tumor Necrosis Factor Inhibitor Drug Customer

12 World Forecast Review for Tumor Necrosis Factor Inhibitor Drug by Geographic Region

12.1 Global Tumor Necrosis Factor Inhibitor Drug Market Size Forecast by Region

12.1.1 Global Tumor Necrosis Factor Inhibitor Drug Forecast by Region (2023-2028)

12.1.2 Global Tumor Necrosis Factor Inhibitor Drug Annual Revenue Forecast by Region (2023-2028)

12.2 Americas Forecast by Country

12.3 APAC Forecast by Region

12.4 Europe Forecast by Country

12.5 Middle East & Africa Forecast by Country

12.6 Global Tumor Necrosis Factor Inhibitor Drug Forecast by Type

12.7 Global Tumor Necrosis Factor Inhibitor Drug Forecast by Application

13 Key Players Analysis

13.1 AbbVie Inc.

13.1.1 AbbVie Inc. Company Information

13.1.2 AbbVie Inc. Tumor Necrosis Factor Inhibitor Drug Product Offered

13.1.3 AbbVie Inc. Tumor Necrosis Factor Inhibitor Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.1.4 AbbVie Inc. Main Business Overview

13.1.5 AbbVie Inc. Latest Developments

13.2 Amgen Inc.

13.2.1 Amgen Inc. Company Information

13.2.2 Amgen Inc. Tumor Necrosis Factor Inhibitor Drug Product Offered

13.2.3 Amgen Inc. Tumor Necrosis Factor Inhibitor Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.2.4 Amgen Inc. Main Business Overview

13.2.5 Amgen Inc. Latest Developments

13.3 Johnson & Johnson

13.3.1 Johnson & Johnson Company Information

13.3.2 Johnson & Johnson Tumor Necrosis Factor Inhibitor Drug Product Offered

13.3.3 Johnson & Johnson Tumor Necrosis Factor Inhibitor Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.3.4 Johnson & Johnson Main Business Overview

13.3.5 Johnson & Johnson Latest Developments

13.4 UCB

13.4.1 UCB Company Information

13.4.2 UCB Tumor Necrosis Factor Inhibitor Drug Product Offered

13.4.3 UCB Tumor Necrosis Factor Inhibitor Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.4.4 UCB Main Business Overview

13.4.5 UCB Latest Developments

13.5 Novartis AG

13.5.1 Novartis AG Company Information

13.5.2 Novartis AG Tumor Necrosis Factor Inhibitor Drug Product Offered

13.5.3 Novartis AG Tumor Necrosis Factor Inhibitor Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.5.4 Novartis AG Main Business Overview

13.5.5 Novartis AG Latest Developments

13.6 Pfizer, Inc.

13.6.1 Pfizer, Inc. Company Information

13.6.2 Pfizer, Inc. Tumor Necrosis Factor Inhibitor Drug Product Offered

13.6.3 Pfizer, Inc. Tumor Necrosis Factor Inhibitor Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.6.4 Pfizer, Inc. Main Business Overview

13.6.5 Pfizer, Inc. Latest Developments

13.7 Merck & Co., Inc.

13.7.1 Merck & Co., Inc. Company Information

13.7.2 Merck & Co., Inc. Tumor Necrosis Factor Inhibitor Drug Product Offered

13.7.3 Merck & Co., Inc. Tumor Necrosis Factor Inhibitor Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.7.4 Merck & Co., Inc. Main Business Overview

13.7.5 Merck & Co., Inc. Latest Developments

13.8 CASI Pharmaceuticals

13.8.1 CASI Pharmaceuticals Company Information

13.8.2 CASI Pharmaceuticals Tumor Necrosis Factor Inhibitor Drug Product Offered

13.8.3 CASI Pharmaceuticals Tumor Necrosis Factor Inhibitor Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.8.4 CASI Pharmaceuticals Main Business Overview

13.8.5 CASI Pharmaceuticals Latest Developments

13.9 EPIRUS Biopharmaceuticals

13.9.1 EPIRUS Biopharmaceuticals Company Information

13.9.2 EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitor Drug Product Offered

13.9.3 EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitor Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.9.4 EPIRUS Biopharmaceuticals Main Business Overview

13.9.5 EPIRUS Biopharmaceuticals Latest Developments

13.10 LEO Pharma

13.10.1 LEO Pharma Company Information

13.10.2 LEO Pharma Tumor Necrosis Factor Inhibitor Drug Product Offered

13.10.3 LEO Pharma Tumor Necrosis Factor Inhibitor Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.10.4 LEO Pharma Main Business Overview

13.10.5 LEO Pharma Latest Developments

13.11 PROBIOMED

13.11.1 PROBIOMED Company Information

13.11.2 PROBIOMED Tumor Necrosis Factor Inhibitor Drug Product Offered

13.11.3 PROBIOMED Tumor Necrosis Factor Inhibitor Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.11.4 PROBIOMED Main Business Overview

13.11.5 PROBIOMED Latest Developments

13.12 Shanghai Pharmaceuticals Holding Co., Ltd.

13.12.1 Shanghai Pharmaceuticals Holding Co., Ltd. Company Information

13.12.2 Shanghai Pharmaceuticals Holding Co., Ltd. Tumor Necrosis Factor Inhibitor Drug Product Offered

13.12.3 Shanghai Pharmaceuticals Holding Co., Ltd. Tumor Necrosis Factor Inhibitor Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.12.4 Shanghai Pharmaceuticals Holding Co., Ltd. Main Business Overview

13.12.5 Shanghai Pharmaceuticals Holding Co., Ltd. Latest Developments

14 Research Findings and Conclusion

Table 1. Tumor Necrosis Factor Inhibitor Drug Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)

Table 2. Tumor Necrosis Factor Inhibitor Drug Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)

Table 3. Major Players of Humira

Table 4. Major Players of Enbrel

Table 5. Major Players of Remicade

Table 6. Major Players of Simponi

Table 7. Major Players of Cimzia

Table 8. Major Players of Biosimilars

Table 9. Global Tumor Necrosis Factor Inhibitor Drug Sales by Type (2017-2022) & (K Units)

Table 10. Global Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Type (2017-2022)

Table 11. Global Tumor Necrosis Factor Inhibitor Drug Revenue by Type (2017-2022) & ($ million)

Table 12. Global Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Type (2017-2022)

Table 13. Global Tumor Necrosis Factor Inhibitor Drug Sale Price by Type (2017-2022) & (US$/Unit)

Table 14. Global Tumor Necrosis Factor Inhibitor Drug Sales by Application (2017-2022) & (K Units)

Table 15. Global Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Application (2017-2022)

Table 16. Global Tumor Necrosis Factor Inhibitor Drug Revenue by Application (2017-2022)

Table 17. Global Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Application (2017-2022)

Table 18. Global Tumor Necrosis Factor Inhibitor Drug Sale Price by Application (2017-2022) & (US$/Unit)

Table 19. Global Tumor Necrosis Factor Inhibitor Drug Sales by Company (2020-2022) & (K Units)

Table 20. Global Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Company (2020-2022)

Table 21. Global Tumor Necrosis Factor Inhibitor Drug Revenue by Company (2020-2022) ($ Millions)

Table 22. Global Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Company (2020-2022)

Table 23. Global Tumor Necrosis Factor Inhibitor Drug Sale Price by Company (2020-2022) & (US$/Unit)

Table 24. Key Manufacturers Tumor Necrosis Factor Inhibitor Drug Producing Area Distribution and Sales Area

Table 25. Players Tumor Necrosis Factor Inhibitor Drug Products Offered

Table 26. Tumor Necrosis Factor Inhibitor Drug Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)

Table 27. New Products and Potential Entrants

Table 28. Mergers & Acquisitions, Expansion

Table 29. Global Tumor Necrosis Factor Inhibitor Drug Sales by Geographic Region (2017-2022) & (K Units)

Table 30. Global Tumor Necrosis Factor Inhibitor Drug Sales Market Share Geographic Region (2017-2022)

Table 31. Global Tumor Necrosis Factor Inhibitor Drug Revenue by Geographic Region (2017-2022) & ($ millions)

Table 32. Global Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Geographic Region (2017-2022)

Table 33. Global Tumor Necrosis Factor Inhibitor Drug Sales by Country/Region (2017-2022) & (K Units)

Table 34. Global Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Country/Region (2017-2022)

Table 35. Global Tumor Necrosis Factor Inhibitor Drug Revenue by Country/Region (2017-2022) & ($ millions)

Table 36. Global Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Country/Region (2017-2022)

Table 37. Americas Tumor Necrosis Factor Inhibitor Drug Sales by Country (2017-2022) & (K Units)

Table 38. Americas Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Country (2017-2022)

Table 39. Americas Tumor Necrosis Factor Inhibitor Drug Revenue by Country (2017-2022) & ($ Millions)

Table 40. Americas Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Country (2017-2022)

Table 41. Americas Tumor Necrosis Factor Inhibitor Drug Sales by Type (2017-2022) & (K Units)

Table 42. Americas Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Type (2017-2022)

Table 43. Americas Tumor Necrosis Factor Inhibitor Drug Sales by Application (2017-2022) & (K Units)

Table 44. Americas Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Application (2017-2022)

Table 45. APAC Tumor Necrosis Factor Inhibitor Drug Sales by Region (2017-2022) & (K Units)

Table 46. APAC Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Region (2017-2022)

Table 47. APAC Tumor Necrosis Factor Inhibitor Drug Revenue by Region (2017-2022) & ($ Millions)

Table 48. APAC Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Region (2017-2022)

Table 49. APAC Tumor Necrosis Factor Inhibitor Drug Sales by Type (2017-2022) & (K Units)

Table 50. APAC Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Type (2017-2022)

Table 51. APAC Tumor Necrosis Factor Inhibitor Drug Sales by Application (2017-2022) & (K Units)

Table 52. APAC Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Application (2017-2022)

Table 53. Europe Tumor Necrosis Factor Inhibitor Drug Sales by Country (2017-2022) & (K Units)

Table 54. Europe Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Country (2017-2022)

Table 55. Europe Tumor Necrosis Factor Inhibitor Drug Revenue by Country (2017-2022) & ($ Millions)

Table 56. Europe Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Country (2017-2022)

Table 57. Europe Tumor Necrosis Factor Inhibitor Drug Sales by Type (2017-2022) & (K Units)

Table 58. Europe Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Type (2017-2022)

Table 59. Europe Tumor Necrosis Factor Inhibitor Drug Sales by Application (2017-2022) & (K Units)

Table 60. Europe Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Application (2017-2022)

Table 61. Middle East & Africa Tumor Necrosis Factor Inhibitor Drug Sales by Country (2017-2022) & (K Units)

Table 62. Middle East & Africa Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Country (2017-2022)

Table 63. Middle East & Africa Tumor Necrosis Factor Inhibitor Drug Revenue by Country (2017-2022) & ($ Millions)

Table 64. Middle East & Africa Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Country (2017-2022)

Table 65. Middle East & Africa Tumor Necrosis Factor Inhibitor Drug Sales by Type (2017-2022) & (K Units)

Table 66. Middle East & Africa Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Type (2017-2022)

Table 67. Middle East & Africa Tumor Necrosis Factor Inhibitor Drug Sales by Application (2017-2022) & (K Units)

Table 68. Middle East & Africa Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Application (2017-2022)

Table 69. Key Market Drivers & Growth Opportunities of Tumor Necrosis Factor Inhibitor Drug

Table 70. Key Market Challenges & Risks of Tumor Necrosis Factor Inhibitor Drug

Table 71. Key Industry Trends of Tumor Necrosis Factor Inhibitor Drug

Table 72. Tumor Necrosis Factor Inhibitor Drug Raw Material

Table 73. Key Suppliers of Raw Materials

Table 74. Tumor Necrosis Factor Inhibitor Drug Distributors List

Table 75. Tumor Necrosis Factor Inhibitor Drug Customer List

Table 76. Global Tumor Necrosis Factor Inhibitor Drug Sales Forecast by Region (2023-2028) & (K Units)

Table 77. Global Tumor Necrosis Factor Inhibitor Drug Sales Market Forecast by Region

Table 78. Global Tumor Necrosis Factor Inhibitor Drug Revenue Forecast by Region (2023-2028) & ($ millions)

Table 79. Global Tumor Necrosis Factor Inhibitor Drug Revenue Market Share Forecast by Region (2023-2028)

Table 80. Americas Tumor Necrosis Factor Inhibitor Drug Sales Forecast by Country (2023-2028) & (K Units)

Table 81. Americas Tumor Necrosis Factor Inhibitor Drug Revenue Forecast by Country (2023-2028) & ($ millions)

Table 82. APAC Tumor Necrosis Factor Inhibitor Drug Sales Forecast by Region (2023-2028) & (K Units)

Table 83. APAC Tumor Necrosis Factor Inhibitor Drug Revenue Forecast by Region (2023-2028) & ($ millions)

Table 84. Europe Tumor Necrosis Factor Inhibitor Drug Sales Forecast by Country (2023-2028) & (K Units)

Table 85. Europe Tumor Necrosis Factor Inhibitor Drug Revenue Forecast by Country (2023-2028) & ($ millions)

Table 86. Middle East & Africa Tumor Necrosis Factor Inhibitor Drug Sales Forecast by Country (2023-2028) & (K Units)

Table 87. Middle East & Africa Tumor Necrosis Factor Inhibitor Drug Revenue Forecast by Country (2023-2028) & ($ millions)

Table 88. Global Tumor Necrosis Factor Inhibitor Drug Sales Forecast by Type (2023-2028) & (K Units)

Table 89. Global Tumor Necrosis Factor Inhibitor Drug Sales Market Share Forecast by Type (2023-2028)

Table 90. Global Tumor Necrosis Factor Inhibitor Drug Revenue Forecast by Type (2023-2028) & ($ Millions)

Table 91. Global Tumor Necrosis Factor Inhibitor Drug Revenue Market Share Forecast by Type (2023-2028)

Table 92. Global Tumor Necrosis Factor Inhibitor Drug Sales Forecast by Application (2023-2028) & (K Units)

Table 93. Global Tumor Necrosis Factor Inhibitor Drug Sales Market Share Forecast by Application (2023-2028)

Table 94. Global Tumor Necrosis Factor Inhibitor Drug Revenue Forecast by Application (2023-2028) & ($ Millions)

Table 95. Global Tumor Necrosis Factor Inhibitor Drug Revenue Market Share Forecast by Application (2023-2028)

Table 96. AbbVie Inc. Basic Information, Tumor Necrosis Factor Inhibitor Drug Manufacturing Base, Sales Area and Its Competitors

Table 97. AbbVie Inc. Tumor Necrosis Factor Inhibitor Drug Product Offered

Table 98. AbbVie Inc. Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)

Table 99. AbbVie Inc. Main Business

Table 100. AbbVie Inc. Latest Developments

Table 101. Amgen Inc. Basic Information, Tumor Necrosis Factor Inhibitor Drug Manufacturing Base, Sales Area and Its Competitors

Table 102. Amgen Inc. Tumor Necrosis Factor Inhibitor Drug Product Offered

Table 103. Amgen Inc. Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)

Table 104. Amgen Inc. Main Business

Table 105. Amgen Inc. Latest Developments

Table 106. Johnson & Johnson Basic Information, Tumor Necrosis Factor Inhibitor Drug Manufacturing Base, Sales Area and Its Competitors

Table 107. Johnson & Johnson Tumor Necrosis Factor Inhibitor Drug Product Offered

Table 108. Johnson & Johnson Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)

Table 109. Johnson & Johnson Main Business

Table 110. Johnson & Johnson Latest Developments

Table 111. UCB Basic Information, Tumor Necrosis Factor Inhibitor Drug Manufacturing Base, Sales Area and Its Competitors

Table 112. UCB Tumor Necrosis Factor Inhibitor Drug Product Offered

Table 113. UCB Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)

Table 114. UCB Main Business

Table 115. UCB Latest Developments

Table 116. Novartis AG Basic Information, Tumor Necrosis Factor Inhibitor Drug Manufacturing Base, Sales Area and Its Competitors

Table 117. Novartis AG Tumor Necrosis Factor Inhibitor Drug Product Offered

Table 118. Novartis AG Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)

Table 119. Novartis AG Main Business

Table 120. Novartis AG Latest Developments

Table 121. Pfizer, Inc. Basic Information, Tumor Necrosis Factor Inhibitor Drug Manufacturing Base, Sales Area and Its Competitors

Table 122. Pfizer, Inc. Tumor Necrosis Factor Inhibitor Drug Product Offered

Table 123. Pfizer, Inc. Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)

Table 124. Pfizer, Inc. Main Business

Table 125. Pfizer, Inc. Latest Developments

Table 126. Merck & Co., Inc. Basic Information, Tumor Necrosis Factor Inhibitor Drug Manufacturing Base, Sales Area and Its Competitors

Table 127. Merck & Co., Inc. Tumor Necrosis Factor Inhibitor Drug Product Offered

Table 128. Merck & Co., Inc. Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)

Table 129. Merck & Co., Inc. Main Business

Table 130. Merck & Co., Inc. Latest Developments

Table 131. CASI Pharmaceuticals Basic Information, Tumor Necrosis Factor Inhibitor Drug Manufacturing Base, Sales Area and Its Competitors

Table 132. CASI Pharmaceuticals Tumor Necrosis Factor Inhibitor Drug Product Offered

Table 133. CASI Pharmaceuticals Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)

Table 134. CASI Pharmaceuticals Main Business

Table 135. CASI Pharmaceuticals Latest Developments

Table 136. EPIRUS Biopharmaceuticals Basic Information, Tumor Necrosis Factor Inhibitor Drug Manufacturing Base, Sales Area and Its Competitors

Table 137. EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitor Drug Product Offered

Table 138. EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)

Table 139. EPIRUS Biopharmaceuticals Main Business

Table 140. EPIRUS Biopharmaceuticals Latest Developments

Table 141. LEO Pharma Basic Information, Tumor Necrosis Factor Inhibitor Drug Manufacturing Base, Sales Area and Its Competitors

Table 142. LEO Pharma Tumor Necrosis Factor Inhibitor Drug Product Offered

Table 143. LEO Pharma Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)

Table 144. LEO Pharma Main Business

Table 145. LEO Pharma Latest Developments

Table 146. PROBIOMED Basic Information, Tumor Necrosis Factor Inhibitor Drug Manufacturing Base, Sales Area and Its Competitors

Table 147. PROBIOMED Tumor Necrosis Factor Inhibitor Drug Product Offered

Table 148. PROBIOMED Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)

Table 149. PROBIOMED Main Business

Table 150. PROBIOMED Latest Developments

Table 151. Shanghai Pharmaceuticals Holding Co., Ltd. Basic Information, Tumor Necrosis Factor Inhibitor Drug Manufacturing Base, Sales Area and Its Competitors

Table 152. Shanghai Pharmaceuticals Holding Co., Ltd. Tumor Necrosis Factor Inhibitor Drug Product Offered

Table 153. Shanghai Pharmaceuticals Holding Co., Ltd. Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)

Table 154. Shanghai Pharmaceuticals Holding Co., Ltd. Main Business

Table 155. Shanghai Pharmaceuticals Holding Co., Ltd. Latest Developments

List of Figures

Figure 1. Picture of Tumor Necrosis Factor Inhibitor Drug

Figure 2. Tumor Necrosis Factor Inhibitor Drug Report Years Considered

Figure 3. Research Objectives

Figure 4. Research Methodology

Figure 5. Research Process and Data Source

Figure 6. Global Tumor Necrosis Factor Inhibitor Drug Sales Growth Rate 2017-2028 (K Units)

Figure 7. Global Tumor Necrosis Factor Inhibitor Drug Revenue Growth Rate 2017-2028 ($ Millions)

Figure 8. Tumor Necrosis Factor Inhibitor Drug Sales by Region (2021 & 2028) & ($ millions)

Figure 9. Product Picture of Humira

Figure 10. Product Picture of Enbrel

Figure 11. Product Picture of Remicade

Figure 12. Product Picture of Simponi

Figure 13. Product Picture of Cimzia

Figure 14. Product Picture of Biosimilars

Figure 15. Global Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Type in 2021

Figure 16. Global Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Type (2017-2022)

Figure 17. Tumor Necrosis Factor Inhibitor Drug Consumed in Rheumatoid Arthritis

Figure 18. Global Tumor Necrosis Factor Inhibitor Drug Market: Rheumatoid Arthritis (2017-2022) & (K Units)

Figure 19. Tumor Necrosis Factor Inhibitor Drug Consumed in Psoriatic Arthritis

Figure 20. Global Tumor Necrosis Factor Inhibitor Drug Market: Psoriatic Arthritis (2017-2022) & (K Units)

Figure 21. Tumor Necrosis Factor Inhibitor Drug Consumed in Juvenile Idiopathic Arthritis

Figure 22. Global Tumor Necrosis Factor Inhibitor Drug Market: Juvenile Idiopathic Arthritis (2017-2022) & (K Units)

Figure 23. Tumor Necrosis Factor Inhibitor Drug Consumed in Crohn’s Disease

Figure 24. Global Tumor Necrosis Factor Inhibitor Drug Market: Crohn’s Disease (2017-2022) & (K Units)

Figure 25. Tumor Necrosis Factor Inhibitor Drug Consumed in Ulcerative Colitis

Figure 26. Global Tumor Necrosis Factor Inhibitor Drug Market: Ulcerative Colitis (2017-2022) & (K Units)

Figure 27. Tumor Necrosis Factor Inhibitor Drug Consumed in Others

Figure 28. Global Tumor Necrosis Factor Inhibitor Drug Market: Others (2017-2022) & (K Units)

Figure 29. Global Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Application (2017-2022)

Figure 30. Global Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Application in 2021

Figure 31. Tumor Necrosis Factor Inhibitor Drug Revenue Market by Company in 2021 ($ Million)

Figure 32. Global Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Company in 2021

Figure 33. Global Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Geographic Region (2017-2022)

Figure 34. Global Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Geographic Region in 2021

Figure 35. Global Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Region (2017-2022)

Figure 36. Global Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Country/Region in 2021

Figure 37. Americas Tumor Necrosis Factor Inhibitor Drug Sales 2017-2022 (K Units)

Figure 38. Americas Tumor Necrosis Factor Inhibitor Drug Revenue 2017-2022 ($ Millions)

Figure 39. APAC Tumor Necrosis Factor Inhibitor Drug Sales 2017-2022 (K Units)

Figure 40. APAC Tumor Necrosis Factor Inhibitor Drug Revenue 2017-2022 ($ Millions)

Figure 41. Europe Tumor Necrosis Factor Inhibitor Drug Sales 2017-2022 (K Units)

Figure 42. Europe Tumor Necrosis Factor Inhibitor Drug Revenue 2017-2022 ($ Millions)

Figure 43. Middle East & Africa Tumor Necrosis Factor Inhibitor Drug Sales 2017-2022 (K Units)

Figure 44. Middle East & Africa Tumor Necrosis Factor Inhibitor Drug Revenue 2017-2022 ($ Millions)

Figure 45. Americas Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Country in 2021

Figure 46. Americas Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Country in 2021

Figure 47. United States Tumor Necrosis Factor Inhibitor Drug Revenue Growth 2017-2022 ($ Millions)

Figure 48. Canada Tumor Necrosis Factor Inhibitor Drug Revenue Growth 2017-2022 ($ Millions)

Figure 49. Mexico Tumor Necrosis Factor Inhibitor Drug Revenue Growth 2017-2022 ($ Millions)

Figure 50. Brazil Tumor Necrosis Factor Inhibitor Drug Revenue Growth 2017-2022 ($ Millions)

Figure 51. APAC Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Region in 2021

Figure 52. APAC Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Regions in 2021

Figure 53. China Tumor Necrosis Factor Inhibitor Drug Revenue Growth 2017-2022 ($ Millions)

Figure 54. Japan Tumor Necrosis Factor Inhibitor Drug Revenue Growth 2017-2022 ($ Millions)

Figure 55. South Korea Tumor Necrosis Factor Inhibitor Drug Revenue Growth 2017-2022 ($ Millions)

Figure 56. Southeast Asia Tumor Necrosis Factor Inhibitor Drug Revenue Growth 2017-2022 ($ Millions)

Figure 57. India Tumor Necrosis Factor Inhibitor Drug Revenue Growth 2017-2022 ($ Millions)

Figure 58. Australia Tumor Necrosis Factor Inhibitor Drug Revenue Growth 2017-2022 ($ Millions)

Figure 59. Europe Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Country in 2021

Figure 60. Europe Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Country in 2021

Figure 61. Germany Tumor Necrosis Factor Inhibitor Drug Revenue Growth 2017-2022 ($ Millions)

Figure 62. France Tumor Necrosis Factor Inhibitor Drug Revenue Growth 2017-2022 ($ Millions)

Figure 63. UK Tumor Necrosis Factor Inhibitor Drug Revenue Growth 2017-2022 ($ Millions)

Figure 64. Italy Tumor Necrosis Factor Inhibitor Drug Revenue Growth 2017-2022 ($ Millions)

Figure 65. Russia Tumor Necrosis Factor Inhibitor Drug Revenue Growth 2017-2022 ($ Millions)

Figure 66. Middle East & Africa Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Country in 2021

Figure 67. Middle East & Africa Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Country in 2021

Figure 68. Egypt Tumor Necrosis Factor Inhibitor Drug Revenue Growth 2017-2022 ($ Millions)

Figure 69. South Africa Tumor Necrosis Factor Inhibitor Drug Revenue Growth 2017-2022 ($ Millions)

Figure 70. Israel Tumor Necrosis Factor Inhibitor Drug Revenue Growth 2017-2022 ($ Millions)

Figure 71. Turkey Tumor Necrosis Factor Inhibitor Drug Revenue Growth 2017-2022 ($ Millions)

Figure 72. GCC Country Tumor Necrosis Factor Inhibitor Drug Revenue Growth 2017-2022 ($ Millions)

Figure 73. Manufacturing Cost Structure Analysis of Tumor Necrosis Factor Inhibitor Drug in 2021

Figure 74. Manufacturing Process Analysis of Tumor Necrosis Factor Inhibitor Drug

Figure 75. Industry Chain Structure of Tumor Necrosis Factor Inhibitor Drug

Figure 76. Channels of Distribution

Figure 77. Distributors Profiles